Holen Sie sich die Stockscreener-App
6.00
10.58%
-0.71
Vorhandelsmarkt:
5.99
-0.010
-0.17%
Schlusskurs vom Vortag:
$6.71
Offen:
$6.58
24-Stunden-Volumen:
20,726
Relative Volume:
0.97
Marktkapitalisierung:
$6.62M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-57.11M
KGV:
-0.40
EPS:
-15
Netto-Cashflow:
$-34.82M
1W Leistung:
-21.16%
1M Leistung:
-8.20%
6M Leistung:
-62.03%
1J Leistung:
-90.16%
1-Tages-Spanne:
$4.9501
$6.58
1-Wochen-Bereich:
$4.9501
$8.70
52-Wochen-Spanne:
$4.9501
$61.00
Apollomics Inc Stock (APLM) Company Profile
Vergleichen Sie APLM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
APLM
Apollomics Inc
|
6.00 | 6.62M | 0 | -57.11M | -34.82M | -15.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Apollomics Inc Aktie (APLM) Neueste Nachrichten
(APLM) Investment Analysis - news.stocktradersdaily.com
APLM stock touches 52-week low at $6 amid market challenges - Investing.com Australia
Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress - The Manila Times
Apollomics Achieves Major Clinical Win: 43% Response Rate Plus New $10M Partnership Deal Extends Runway - Stock Titan
Apollomics and LaunXP ink $50 M deal for NSCLC treatment in Asia - BioSpectrum Asia
Apollomics and LaunXP agree on NSCLC treatment in Asia - Yahoo
Apollomics, Inc. (NASDAQ:APLMW) Sees Significant Growth in Short Interest - Defense World
Apollomics, LaunXP enter development, commercial agreement for Vebreltinib - MSN
Apollomics Signs Exclusive Development, Commercialization Deal for Vebreltinib in Asia - MarketScreener
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib - GlobeNewswire
$60M Deal: Apollomics' Lung Cancer Drug Breakthrough Expands Across Asia - Stock Titan
Better Artificial Intelligence Stock: SoundHound AI vs. C3.ai - The Globe and Mail
Apollomics Inc. and LaunXP International Co., Ltd., Affiliate of LaunXP Biomedical Co., Ltd. Announce Development and Commercialization Agreement for Vebreltinib - MarketScreener
(APLM) Long Term Investment Analysis - news.stocktradersdaily.com
Why Coinbase (COIN) Stock Is Trading Up Today - The Globe and Mail
Apollomics, Inc. (NASDAQ:APLMW) Short Interest Update - Defense World
These Were the 2 Top-Performing Stocks in the S&P 500 in February 2025 - The Globe and Mail
(APLM) Trading Advice - Stock Traders Daily
Apollomics, Inc. (NASDAQ:APLMW) Sees Large Decrease in Short Interest - Defense World
APLM Stock Hits 52-Week Low at $6.2 Amid Steep Yearly Decline - Investing.com Australia
APLM Stock Hits 52-Week Low at $6.2 Amid Steep Yearly Decline By Investing.com - Investing.com South Africa
APLM stock touches 52-week low at $6.38 amid market challenges - MSN
APLM stock touches 52-week low at $6.38 amid market challenges By Investing.com - Investing.com South Africa
Objective long/short (APLM) Report - Stock Traders Daily
Apollomics, Inc. (NASDAQ:APLMW) Sees Significant Decrease in Short Interest - Defense World
Apollomics phase 3 trial in China shows no benefit - Investing.com India
Biotech fails trials for its leukemia drug - Silicon Valley Business Journal
Apollomics Shares Down in Premarket After Leukemia Drug Misses Phase-3 Targets - MarketWatch
Apollomics Announces Top-line Results for Phase 3 Bridging - GlobeNewswire
Apollomics' Cancer Drug Disappoints in Phase 3 Trial with Lower Survival Rates, Program Terminated - StockTitan
Apollomics Meets Nasdaq Compliance On Bid Price Requirement - Nasdaq
APLM Stock Hits 52-Week Low at $7.51 Amid Market Challenges - Investing.com Australia
APLM Stock Hits 52-Week Low at $7.51 Amid Market Challenges By Investing.com - Investing.com South Africa
Apollomics Regains Compliance with Nasdaq’s Minimum Bid Price Requirement - GlobeNewswire
Apollomics Secures Nasdaq Listing Status After Meeting Crucial Price Requirements - StockTitan
When the Price of (APLM) Talks, People Listen - Stock Traders Daily
Apollomics Inc trading halted, news pending - MSN
Apollomics, Inc. Appoints Matthew Plunkett as Chief Financial Officer - Marketscreener.com
APLM Stock Plummets to 52-Week Low, Hits $8.01 Amid Market Turbulence - Investing.com India
APLM Stock Plummets to 52-Week Low, Hits $8.01 Amid Market Turbulence By Investing.com - Investing.com South Africa
Apollomics, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 - Marketscreener.com
Apollomics Shares to Reverse Split on Monday, November 25th (NASDAQ:APLM) - Defense World
Apollomics announces 1-for-100 reverse stock split By Investing.com - Investing.com South Africa
Apollomics announces 1-for-100 reverse stock split - Investing.com
Apollomics’ Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split - GlobeNewswire
Apollomics Implements 1-for-100 Reverse Stock Split, Adjusts Warrant Prices | APLM Stock News - StockTitan
Spotlight on Undervalued Nasdaq Stocks: HCWB, CRDL, NIVF, SINT, APLMA Must-Watch This Week! - Marketscreener.com
Stock market today: CareMax(−41.19%), HCW Biologics(+209.06%) among the most volatile stocks in early trading - Business Upturn
Apollomics, Inc. (NASDAQ:APLM) Sees Significant Drop in Short Interest - Defense World
Apollomics Inc (APLM): Major Improvements, Need To Be Considered - Stocks Register
Finanzdaten der Apollomics Inc-Aktie (APLM)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):